High-ferritin-target intravenous ferric carboxymaltose,
does it really help with Hemoglobin response in iron-deficiency anemia with nondialysis chronic kidney disease?
research showsThe grade is C. FIND-CKD's exact primary endpoint was initiation of other anemia management or two consecutive hemoglobin values below 10 g/dL during weeks 8 to 52, not simply hemoglobin response. It occurred in 23.5% versus 31.8%, HR 0.65 (95% CI 0.44 to 0.95), absolute difference -8.3 points. A hemoglobin rise of at least 1 g/dL was also more frequent, but these remain surrogate and treatment-decision outcomes.
ads claimA higher hemoglobin response must not be expanded into less dialysis, longer survival, or cardiovascular protection. Verdict 2560 is D with 34 points for the same drug in a different setting: preoperative preparation rather than chronic anemia management.
Useful facts when choosing a product
- The high target was ferritin 400 to 600 µg/L.
- Oral control was ferrous sulfate providing 100 mg iron twice daily.
- This was an open-label Vifor Pharma-sponsored trial.
What the research actually shows
Four gates: ① substantial attrition, open-label subjective component, and active-control-only; ② the listed ≥15% attrition, unblinded subjective endpoint, and active-control-only items; ③ 519/626 (82.9%) completed, clinician decisions to start ESA, transfusion, or alternative iron entered the primary composite in an open-label trial, and oral iron was the only comparator; ④ more complete follow-up, blinded treatment decisions, and double-dummy placebo control were technically feasible, so all three were avoidable. Two or more map to the same bias category. Central interactive voice-response randomization was used. Vifor Pharma sponsored the trial and supplied oral iron.
Why this is classified as C (50)
A manufacturer-funded single trial improved surrogate outcomes but had overlapping open-label, attrition, and active-control limitations, giving C with 50 points.
Counterpoint. Patient-event efficacy and long-term safety require larger dedicated trials.
Rejudgment record. Cross-check applied — An open-label manufacturer trial improved a hemoglobin-centered surrogate composite but was not powered for patient events or safety
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Hemoglobin-centered response | C | The surrogate composite improved. |
| Reduced dialysis, death, or cardiovascular events | ? | The trial was not designed or powered to answer these events. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | 56-week multicenter randomized open-label three-arm active-control trial | 519 | Sponsored by Vifor Pharma, which also supplied oral iron | Initiation of other anemia management or two consecutive Hb values below 10 g/dL during weeks 8-52 | 23.5% vs 31.8%; HR 0.65 (0.44 to 0.95), absolute difference -8.3 points, NNT 12 | Pivotal manufacturer-funded surrogate evidence |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-08-26).
Final verification and publication gate: Codex · Verification cutoff: 2026-08-26 · Corrections: none
Cite this verdict
[Chamgap] Benefit of High-Ferritin-Target Intravenous Ferric Carboxymaltose × Hemoglobin Response in Non-Dialysis Chronic Kidney Disease Anemia, a Surrogate Outcome — Evidence Grade C·50. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/energy/high-ferritin-ferric-carboxymaltose-hemoglobin-response-nondialysis-ckd-anemia/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.